Elite Pharmaceuticals Awarded Second U.S. Patent for Abuse Resistant Drug Formulation

Elite Pharmaceuticals Awarded Second U.S. Patent for Abuse Resistant Drug
Formulation

NORTHVALE, N.J., April 23, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals,
Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the issuance of
U.S. Patent No. 8,425,933 entitled "Abuse-Resistant Oral Dosage Forms and
Method of Use Thereof" by the United States Patent and Trademark Office. This
is the second issued U.S. patent covering Elite's abuse resistant technology
for opioid products.Elite has additional patents pending in the U.S., Canada
and Europe.

"We are pleased to receive this second abuse resistant patent. The recent
guidances and actions by the FDA related to extended release opioids and
specifically oxycodone demonstrates the FDA support for abuse resistant
technologies.Opioid products incorporating abuse resistant technologies have
become a public health priority and these recent actions appear to be a major
step towards the FDA eventually requiring that all extended release opioids
utilize these technologies.This validates our approach and we believe
substantially increases the value of our intellectual property and the abuse
resistant products in our pipeline,"said Jerry Treppel, Elite's Chairman and
CEO.

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release
products. Elite's strategy includes assisting partner companies in the life
cycle management of products to improve off-patent drug products and
developing generic versions of controlled release drug products with high
barriers to entry. Elite has three commercial products currently being sold,
three additional products approved and soon to be launched, and one additional
product pending approval by the FDA. Elite's lead pipeline products include
abuse resistant opioids utilizing the Company's patented proprietary
technology, and a once-daily opioid.They are sustained release oral
formulations of opioids for the treatment of chronic pain, which address two
of the limitations of existing oral opioids: the provision of consistent
relief of baseline pain levels and deterrence of potential abuse.Elite also
provides contract manufacturing for Actavis and Ascend Laboratories
(previously a subsidiary of ThePharmaNetwork and now a subsidiary of Alkem
Laboratories Ltd.) and has partnered with Mikah Pharma to develop a new
product, with Hi-Tech Pharmacal to develop an intermediate for a generic
product, and a Hong Kong based company to develop a branded product for the
United States market and its territories.Elite operates a GMP and DEA
registered facility for research, development, and manufacturing located in
Northvale, NJ.

This news release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Including those related
to the effects, if any, on future results, performance or other expectations
that may have some correlation to the subject matter of this press
release,readers are cautioned that such forward-looking statements involve
risks and uncertainties including, without limitation, delays, uncertainties,
inability to obtain necessary ingredients and other factors not under the
control of Elite, which may cause actual results, performance or achievements
of Elite to be materially different from the results, performance or other
expectations that may be implied by these forward-looking statements These
risks and other factors, including, without limitation, the timing or results
of pending and future clinical trials, regulatory reviews and approvals by the
Food and Drug Administration and other regulatory authorities,intellectual
property protections and defenses, and the Company's ability to operate as a
going concern, are discussed in Elite's filings with the Securities and
Exchange Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite
undertakes no obligation to update any forward-looking statements.

CONTACT: Elite Pharmaceuticals, Inc.
         Dianne Will, Investor Relations, 518-398-6222
         Dianne@elitepharma.com

Elite Pharmaceuticals, Inc Logo
 
Press spacebar to pause and continue. Press esc to stop.